definiens: ) . A s used in this Agreement, the term shall mean a polynucleotide, oligonucleotide or oligonucleotid e analog which hybridizes in a sequence specific mann er under physiological conditions to RNA or DNA . An oligonucleotide analog may include naturally occurr ing or non - natural heterocycles, sugar and/or backb one linkages, and may be molecules in which the sugar m ay be absent, in which the backbone linkages may be phosphate based, amide based, or based on other che mistries and which may or may not include stem loop or structural units . For purposes of clarification, does not include polynucleotides, oligonu cleotides and oligonucleotide analogs that are designed to have e nhanced content of CpG or other immunomodulatory sequences such as in the stem loop or structural un its, for increasing immunomodulatory effects . The p arties acknowledge that drugs that are designed to work th rough an antisense mechanism may happen to contain CpG and/or other immunomodulatory sequences and may, as a secondary mechanism of action, happen to cause immune stimulation . Such drugs will be deemed to be antisense hereunder, as long as such drugs were no t enhanced to have such immunomodulatory properties d uring the design process